Panel of internationally renowned researchers and clinicians will guide development of Delpor’s drug delivery based products in schizophrenia, hepatitis C, diabetes, and other diseases.
SAN FRANCISCO, CA, July 13, 2011 – Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery of antipsychotics and biologics, today announced that a panel of internationally renowned researchers and clinicians will serve as its Scientific Advisory Board to guide development of its novel therapeutics to combat a wide range of diseases.
The Scientific Advisory Board includes the following individuals:
Peter J. Weiden, MD, Director, Psychotic Disorders Program, University of Illinois at Chicago: Dr. Weiden’s research career has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia. He has published extensively on the problem of medication nonadherence with antipsychotic medications among persons with schizophrenia.
Alan F. Schatzberg, MD, Professor of Psychiatry, Stanford University: Dr. Schatzberg is the former Chairman of the Department of Psychiatry and Behavioral Sciences at Stanford University. He has authored over 600 publications and abstracts, including the Manual of Clinical Psychopharmacology, whose seventh edition was published in 2010.
Phyllis Gardner, MD, Professor of Medicine, Stanford University: Dr. Gardner is a professor of medicine, clinical pharmacology at Stanford University. She has over 25 years of experience in academia, medicine and industry including Vice President of Research at ALZA and Head of ALZA Technology Institute.
Costis Maglaras, PhD, Professor of Business, Columbia University: Dr. Maglaras is the David and Lyn Silfen Professor of Business at Columbia University. He is the recipient of several research and teaching awards, and he teaches and serves as faculty director for the executive education course on Risk Management offered by Columbia Business School.
Kevin E. Healy, PhD, Professor, Departments of Bioengineering and Materials Science, UC Berkeley: Dr. Healy is the chairman of the Bioengineering department at UC Berkeley. His work emphasizes the relationship between materials and the cells or tissues they contact. He has extensive experience with drug delivery systems. Major discoveries from his laboratory have centered on the control of cell fate and tissue formation in contact with materials that are tunable in both their biological content and mechanical properties.
Stelios Tzannis, PhD, Biotechnology and Drug Delivery Executive and Researcher: Dr. Tzannis is an industry veteran who has held R&D leadership positions at ALZA Corporation as well as Nektar Therapeutics. At ALZA, he was part of the scientific team for Biopharmaceutical & Implant R&D where he spearheaded the development of an implantable system for the delivery of peptides and proteins.
“We are excited to have a world-class Scientific Advisory Board that includes some of the most respected researchers in the fields of schizophrenia, bipolar, and drug delivery” said Tassos Nicolaou, President and CEO of Delpor. “Each one of our advisors brings valuable expertise that will contribute to the drug development advancement of our products.”
Tassos Nicolaou continued: “Dr. Weiden and Dr. Schatzberg bring valuable expertise related to improving patient outcomes and understanding patient and physician preferences when treating schizophrenia and other mental illnesses, Dr. Gardner is an expert in drug delivery and clinical pharmacology, Dr. Healy is an expert in the properties and biocompatibility of materials used in drug delivery, Dr. Maglaras is an expert in risk management, and Dr. Tzannis brings tremendous expertise in both biopharmaceutical product development as well as in the development of drug delivery implantable systems.”
About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of antipsychotics (in order to improve medication adherence, tolerance, and safety) as well as delivery of biologics in order to improve patient safety and convenience. The company’s lead products include 3-month formulations of Risperidone, Paliperidone, and Interferon-alpha. Additional information about the company can be found at www.delpor.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Tassos Nicolaou, President and CEO